Clinical Trials – Completed
Completed mesothelioma clinical trials have treated all study patients and finished collecting data. Once a study is completed, researchers examine the results. They will determine how and if to move forward with the treatment or technology at hand. Completed studies have improved mesothelioma survival.
Learn About Mesothelioma Clinical Trials in Our Free Guide
Completed Mesothelioma Clinical Trials
Clinical trials may help researchers better understand mesothelioma development and treatment. Clinical studies are considered completed once all treatments and follow-ups are done. This means researchers have collected the last data point from the last patient undergoing treatment. At this point, researchers examine the study results.
In the case of a clinical trial on mesothelioma treatment, this analysis helps answer many questions, including:
- Was the treatment effective?
- Did the benefits of the treatment outweigh the risks?
- Does the treatment require further study?
- Should the treatment be approved by the U.S. Food and Drug Administration (FDA)?
Once study coordinators have finished analyzing results, they may publish them in a medical journal. They may also share the study results in the trial’s ClinicalTrials.gov record.
For more information on clinical trials phases, processes, costs and enrollment, you can visit our Clinical Trials Overview page.
Mesothelioma Advances From Clinical Trials
Some completed clinical trials have tested treatments that substantially improved the prognosis for mesothelioma. Below are a few examples of noteworthy, completed mesothelioma clinical trials.
Study Name: CheckMate-743
Study Purpose: To evaluate an immunotherapy combination treatment compared to standard chemotherapy (cisplatin and pemetrexed)
New Treatment: Opdivo® (nivolumab) and Yervoy® (ipilimumab)
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Improved survival. Patients treated with Opdivo® and Yervoy® had a median survival of 18.1 months. Those treated with standard chemotherapy had a median survival of 14.1 months.
FDA Approval Status: The FDA approved Opdivo® and Yervoy® for treatment of inoperable pleural mesothelioma in October 2020.
Study Name: STELLAR
Study Purpose: To determine the effect of a novel, electric field-based treatment for pleural mesothelioma
New Treatment: Novo-TTF-100L System
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Encouraging survival without increased systemic toxicity. Patients had standard chemotherapy treatment followed by Novo-TTF treatment. Median overall survival was 18.2 months, which compares favorably to other treatment options.
FDA Approval Status: The Novo-TTF-100L System gained FDA approval in 2019. It is approved for the treatment of inoperable pleural mesothelioma in combination with standard chemotherapy. Since the approval, the treatment has become more widely available to mesothelioma patients.
Study Name: MAPS (Mesothelioma Avastin® Plus Pemetrexed-cisplatin Study)
Study Purpose: To determine the effect of an immunotherapy drug on the survival of patients also undergoing standard chemotherapy treatment
New Treatment: Avastin® (bevacizumab)
Type of Mesothelioma: Inoperable pleural mesothelioma
Most Important Result: Improved survival. Patients treated with chemotherapy and Avastin® had a median survival of 18.8 months. Those treated with chemotherapy alone had a median survival of 16.1 months.
FDA Approval Status: The manufacturer did not submit an application for FDA approval. However, experts say Avastin® may be offered to patients who can tolerate it.
Completed Mesothelioma Clinical Trials List
Provided below is a list of completed mesothelioma trials.
Conditions: Mesothelioma
Last Updated: 3/5/2026
Status: Completed
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 1/22/2026
Status: Completed
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: Mesothelioma
Last Updated: 1/16/2026
Status: Completed
Conditions: Mesothelioma
Last Updated: 12/18/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 11/26/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 11/4/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/14/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/5/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/15/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/14/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/9/2025
Status: Completed
CART-meso in Mesothelin Expressing Cancers
Conditions: Mesothelioma
Last Updated: 6/29/2025
Status: Completed
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/24/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 6/13/2025
Status: Completed
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Conditions: Mesothelioma
Last Updated: 6/5/2025
Status: Completed
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Conditions: Mesothelioma
Last Updated: 5/13/2025
Status: Completed
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Mesothelioma
Last Updated: 4/29/2025
Status: Completed
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Conditions: Mesothelioma
Last Updated: 2/19/2025
Status: Completed
Conditions: Mesothelioma
Last Updated: 2/7/2025
Status: Completed
The Registry of Oncology Outcomes Associated with Testing and Treatment
Conditions: Mesothelioma
Last Updated: 12/18/2024
Status: Completed
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Conditions: Mesothelioma
Last Updated: 12/9/2024
Status: Completed
Conditions: Mesothelioma
Last Updated: 10/26/2024
Status: Completed
HIPEC for Peritoneal Carcinomatosis
Conditions: Mesothelioma
Last Updated: 10/24/2024
Status: Completed
Conditions: Mesothelioma
Last Updated: 10/9/2024
Status: Completed
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: 7/31/2024
Status: Completed
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: 7/1/2024
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/21/2024
Status: Completed
Conditions: Mesothelioma
Last Updated: 1/3/2024
Status: Completed
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: 12/20/2023
Status: Completed
Conditions: Mesothelioma
Last Updated: 10/23/2023
Status: Completed
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Conditions: Mesothelioma
Last Updated: 10/19/2023
Status: Completed
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma
Last Updated: 10/4/2023
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/15/2023
Status: Completed
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Conditions: Mesothelioma
Last Updated: 8/25/2023
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/1/2023
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/5/2023
Status: Completed
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 7/3/2023
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/20/2023
Status: Completed
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: 2/8/2023
Status: Completed
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: 12/1/2022
Status: Completed
Dasatinib in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/31/2022
Status: Completed
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/4/2022
Status: Completed
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/29/2022
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/27/2022
Status: Completed
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/22/2022
Status: Completed
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 8/23/2022
Status: Completed
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Conditions: Mesothelioma
Last Updated: 7/20/2022
Status: Completed
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Conditions: Mesothelioma
Last Updated: 6/14/2022
Status: Completed
Phase I Trial HIPEC With Nal-irinotecan
Conditions: Mesothelioma
Last Updated: 5/6/2022
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/28/2022
Status: Completed
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: 4/14/2022
Status: Completed
A Study of LY3023414 in Participants With Advanced Cancer
Conditions: Mesothelioma
Last Updated: 4/8/2022
Status: Completed
Conditions: Mesothelioma
Last Updated: 2/10/2022
Status: Completed
Intravenous Magnesium in Patients Receiving Cisplatin
Conditions: Mesothelioma
Last Updated: 1/11/2022
Status: Completed
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Conditions: Mesothelioma
Last Updated: 12/9/2021
Status: Completed
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Conditions: Mesothelioma
Last Updated: 11/15/2021
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/18/2021
Status: Completed
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Conditions: Mesothelioma
Last Updated: 7/20/2021
Status: Completed
Olaparib in People With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 4/9/2021
Status: Completed
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 4/9/2021
Status: Completed
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 1/11/2021
Status: Completed
Conditions: Mesothelioma
Last Updated: 12/19/2020
Status: Completed
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Conditions: Mesothelioma
Last Updated: 11/4/2020
Status: Completed
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Conditions: Mesothelioma
Last Updated: 10/30/2020
Status: Completed
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/20/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/30/2020
Status: Completed
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Conditions: Mesothelioma
Last Updated: 8/3/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/20/2020
Status: Completed
Clinical and Histopathologic Characteristics of BAP1 Mutations
Conditions: Mesothelioma
Last Updated: 7/1/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 6/26/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/26/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/13/2020
Status: Completed
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 4/10/2020
Status: Completed
Gene Therapy for Pleural Malignancies
Conditions: Mesothelioma
Last Updated: 3/18/2020
Status: Completed
Combination Gene Transfer and Chemotherapy
Conditions: Mesothelioma
Last Updated: 3/17/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/6/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/2/2020
Status: Completed
Conditions: Mesothelioma
Last Updated: 11/7/2019
Status: Completed
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/30/2019
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/30/2019
Status: Completed
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/23/2019
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/17/2019
Status: Completed
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Conditions: Mesothelioma
Last Updated: 7/18/2019
Status: Completed
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/6/2019
Status: Completed
18F-FSPG PET/CT for Cancer Patients on Therapy
Conditions: Mesothelioma
Last Updated: 1/3/2019
Status: Completed
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/16/2018
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/3/2018
Status: Completed
Conditions: Mesothelioma
Last Updated: 6/7/2018
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/10/2018
Status: Completed
Conditions: Mesothelioma
Last Updated: 1/23/2018
Status: Completed
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: 11/29/2017
Status: Completed
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Conditions: Mesothelioma
Last Updated: 11/7/2017
Status: Completed
Autologous Redirected RNA Meso-CIR T Cells
Conditions: Mesothelioma
Last Updated: 9/19/2017
Status: Completed
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
Conditions: Mesothelioma
Last Updated: 7/21/2017
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/24/2017
Status: Completed
Conditions: Mesothelioma
Last Updated: 1/23/2017
Status: Completed
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 12/7/2016
Status: Completed
Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Mesothelioma
Last Updated: 10/28/2016
Status: Completed
Conditions: Mesothelioma
Last Updated: 9/30/2016
Status: Completed
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 8/11/2016
Status: Completed
Capecitabine in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 7/14/2016
Status: Completed
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 7/1/2016
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/2/2016
Status: Completed
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 11/18/2015
Status: Completed
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Conditions: Mesothelioma
Last Updated: 11/18/2015
Status: Completed
B-Receptor Signaling in Cardiomyopathy
Conditions: Mesothelioma
Last Updated: 11/17/2015
Status: Completed
Intrapleural Gene Transfer for Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/22/2015
Status: Completed
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Conditions: Mesothelioma
Last Updated: 7/8/2015
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/8/2015
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/12/2015
Status: Completed
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Conditions: Mesothelioma
Last Updated: 4/30/2015
Status: Completed
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: 4/30/2015
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/29/2015
Status: Completed
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 2/24/2015
Status: Completed
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Mesothelioma
Last Updated: 7/31/2014
Status: Completed
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Conditions: Mesothelioma
Last Updated: 7/24/2014
Status: Completed
Conditions: Mesothelioma
Last Updated: 7/17/2014
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/27/2014
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/27/2014
Status: Completed
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Conditions: Mesothelioma
Last Updated: 3/5/2014
Status: Completed
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Conditions: Mesothelioma
Last Updated: 3/5/2014
Status: Completed
Conditions: Mesothelioma
Last Updated: 2/11/2014
Status: Completed
Rapamycin With Grapefruit Juice for Advanced Malignancies
Conditions: Mesothelioma
Last Updated: 1/17/2014
Status: Completed
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
Conditions: Mesothelioma
Last Updated: 7/10/2013
Status: Completed
Alanosine in Treating Patients With Cancer
Conditions: Mesothelioma
Last Updated: 6/26/2013
Status: Completed
Conditions: Mesothelioma
Last Updated: 6/19/2013
Status: Completed
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Conditions: Mesothelioma
Last Updated: 6/5/2013
Status: Completed
SU5416 in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/3/2013
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/17/2013
Status: Completed
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Conditions: Mesothelioma
Last Updated: 1/24/2013
Status: Completed
Gefitinib in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 1/17/2013
Status: Completed
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Conditions: Mesothelioma
Last Updated: 1/16/2013
Status: Completed
Conditions: Mesothelioma
Last Updated: 10/8/2012
Status: Completed
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Conditions: Mesothelioma
Last Updated: 7/30/2012
Status: Completed
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
Conditions: Mesothelioma
Last Updated: 3/15/2012
Status: Completed
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Conditions: Mesothelioma
Last Updated: 3/15/2012
Status: Completed
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Conditions: Mesothelioma
Last Updated: 12/26/2011
Status: Completed
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Conditions: Mesothelioma
Last Updated: 9/27/2011
Status: Completed
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
Conditions: Mesothelioma
Last Updated: 4/26/2011
Status: Completed
Conditions: Mesothelioma
Last Updated: 4/8/2011
Status: Completed
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 3/28/2011
Status: Completed
Conditions: Mesothelioma
Last Updated: 3/7/2011
Status: Completed
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: 3/1/2011
Status: Completed
Conditions: Mesothelioma
Last Updated: 8/3/2010
Status: Completed
Conditions: Mesothelioma
Last Updated: 5/12/2009
Status: Completed
Conditions: Mesothelioma
Last Updated: 1/26/2007
Status: Completed
Sources
American Cancer Society. Deciding Whether to Be Part of a Clinical Trial. Updated August 2020.
American Cancer Society. What’s New in Malignant Mesothelioma Research? Updated May 2019.
Ghirardelli P, Franceschini D, et al. Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. Lung Cancer. February 2021;152:1-6. doi: 10.1016/j.lungcan.2020.11.022
Kindler HL, Ismaila N, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394
Lau B, Boyer M, et al. Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clinical Lung Cancer. July 2020;21(4):378-383.e1. doi: 10.1016/j.cllc.2020.01.007
Moffitt Cancer Center. Mesothelioma Clinical Trials.
National Cancer Institute. Paying for Clinical Trials. Updated February 2020.
National Cancer Institute. What Are Clinical Trials? Updated November 2021.
National Institute on Aging. Clinical Trials: Benefits, Risks, and Safety. Updated May 2017.
National Institute on Aging. Common Questions About Participating in Alzheimer’s and Related Dementias Research.
National Institutes of Health. NIH Clinical Research Trials and You: The Basics. Updated October 2017.
Novocure. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma. May 2019.
Rintoul RC, Ritchie AJ, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. September 2014;384(9948):1118-27. doi: 10.1016/S0140-6736(14)60418-9
Warnock C, Lord K, et al. Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2). Trials. October 2019;20(1):598. doi: 10.1186/s13063-019-3692-x
Yap TA, Nakagawa K, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. The Lancet Respiratory Medicine. June 2021;9(6):613-621. doi: 10.1016/S2213-2600(20)30515-4
Zalcman G, Mazieres J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. April 2016;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6
Free Mesothelioma Treatment Guide
Katy Moncivais, Ph.D., has more than 15 years of experience as a medical communicator. As the Medical Editor at Mesothelioma.com, she ensures our pages and posts present accurate, helpful information.
Annette Charlevois is a Patient Support Coordinator for Mesothelioma.com. For more than 20 years, she has helped thousands of mesothelioma patients and their families get the assistance they need.
